Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 53 institutions reported holding it in 13F filings for Q3 2026, worth $49.8M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $30.5M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, −2 vs. previous quarter
- 53
- 13F valueReported value at the end of Q3 2026
- $49.8M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$43.4M
- No comparable prior period
- Free cash flow, FY2025
- -$38.6M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 366.6K
- Shares sold short
- Change
- +60.2K
- +19.7% vs. previous
- Days to cover
- 5.43
- At average daily volume
Superinvestors holding KLRS, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding KLRS at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Kalaris Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 22, 2026 (view filing)7:47 PM ET | May 20 | 2 days | Akkaraju Srinivas and 4 othersDirector, 10% Owner | PPurchase | +244.3K | $4.83 | +$1.18M | +12.3%2.22M after | |
| Mar 23, 2026 (view filing) | Mar 20 | 3 days | Hagen Brett RChief Accounting Officer | SSale | −1.92K | $6.72 | −$12.9K | −100.0%0 after | |
| Feb 17, 2026 (view filing)8:15 PM ET | Dec 18, 2025 | 61 daysLate | Akkaraju Srinivas and 4 othersDirector, 10% Owner | PPurchase | +479.8K | $10.42 | +$5.00M | +32.0%1.98M after | |
| Mar 27, 2025 (view filing) | Mar 26 | 1 day | Hagen Brett RChief Accounting Officer | SSale | −907 | $8.97 | −$8.14K | −32.0%1.93K after | |
| Feb 24, 2025 (view filing) | Feb 21 | 3 days | Sinha VikasSee Remarks | SSale | −303 | $10.08 | −$3.05K | −0.6%49.1K after | |
| Feb 24, 2025 (view filing) | Feb 21 | 3 days | Hagen Brett RChief Accounting Officer | SSale | −96 | $10.08 | −$967.68 | −3.3%2.83K after | |
| Feb 24, 2025 (view filing) | Feb 21 | 3 days | Miller EdwardGeneral Counsel | SSale | −106 | $10.08 | −$1.07K | −1.6%6.52K after | |
| Jan 27, 2025 (view filing) | Jan 23 | 4 days | Miller EdwardGeneral Counsel | SSale | −52 | $9.50 | −$493.85 | −0.8%6.62K after | 2 lots |
| Jan 27, 2025 (view filing) | Jan 23 | 4 days | Hagen Brett RChief Accounting Officer | SSale | −36 | $9.50 | −$342.16 | −1.2%2.93K after | 2 lots |
| Jan 27, 2025 (view filing) | Jan 23 | 4 days | Sinha VikasSee Remarks | SSale | −129 | $9.50 | −$1.23K | −0.3%49.4K after | 2 lots |
Top 10 13F holders, Q3 2026
See all 53 holdersThe largest institutional positions in Kalaris Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Samsara BioCapital, LLC | 12,881,175 | $37.2M | 3.54% | 00.0% | Unchanged |
| RTW Investments, LP | 1,300,000 | $3.76M | 0.04% | 00.0% | Unchanged |
| Alyeska Investment Group, L.P. | 472,687 | $1.37M | 0.00% | −100,000−17.5% | Reduced |
| Siren, L.L.C. | 356,559 | $1.03M | 0.02% | −79,239−18.2% | Reduced |
| Vanguard Capital Management LLC | 330,928 | $956.4K | 0.00% | −67,784−17.0% | Reduced |
| Ikarian Capital, LLC | 248,257 | $717.5K | 0.14% | −111,743−31.0% | Reduced |
| Renaissance Technologies LLC | 176,863 | $511.1K | 0.00% | +27,512+18.4% | Added |
| Verdad Advisers, LP | 140,232 | $405.3K | 0.43% | +59,935+74.6% | Added |
| UBS Group AG | 110,187 | $318.4K | 0.00% | −151,944−58.0% | Reduced |
| Raymond James Financial Inc | 101,496 | $293.3K | 0.00% | +4,332+4.5% | Added |
Holders of 5% or more of KLRS
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Kalaris Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Samsara BioCapital, L.P. | 13D/A | 54.20%12.9M shares | −2.30 ppfrom 56.50% | Mar 25, 20254 filings | May 22, 2026 | SEC |
| RTW Investments, LP | 13G | 5.70%1.30M shares | New | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
| Coastlands Capital LP | 13G | 5.69%1.36M shares | New | Oct 26, 20261 filing | Oct 26, 2026 | SEC |